

May 02, 2024

To, The Corporate Relations Department The BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Ref:- Scrip Code:- 500126

The Listing Department The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block,

Bandra Kurla Complex, Bandra (East), Mumbai - 400051 **Ref:- Symbol:- PGHL**

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter ended March 31, 2024

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 5:52 p.m. and ended at 7:49 p.m.), the Unaudited Financial Results for the quarter ended March 31, 2024 were approved.

To,

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2024;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2024 furnished by Statutory Auditors of the Company.

Kindly take the same on record and oblige.

Thanking you, Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani **Company Secretary**

> **Procter & Gamble Health Limited** CIN: L99999MH1967PLC013726 Registered Office: Ground Floor and First Floor, P&G Plaza, Cardinal Gracias Road, Chakala, Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000 www.pghealthindia.com

		aza, Cardinal Gracias Road, Chakala, / 99MH1967PLC013726, email: investo					
	CIN NO. 1353	991011907PLC013720, email. mvestc	ngnevance.im@pg.o	UIII			
	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 MARCH 2024						(₹ in lakhs)
Sr. No.	Particulars	(1) Three months ended 31st March 2024	(2) Preceding Three months ended 31st December 2023	(3) Corresponding Three months ended 31st March 2023	(4) Nine Months ended 31st March 2024	(5) Nine Months ended 31st March 2023	(6) Year ended 30th June 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Revenue from Operations	25,248	30,997	32,092	86,738	92,844	122,9
2.	Other Income	227	518	497	1,350	1,293	1,8
з.	Total income (1+2)	25,475	31,515	32,589	88,088	94,137	124,8
4.	Expenses a) Cost of materials consumed b) Purchases of stock-in-trade c) Changes in inventories of finished goods,work-in-progress and stock in trade	6,466 1,113 (193)	7,084 840 1,115	6,362 2,049 1,595	22,281 2,095 763	24,492 3,338 (1,033)	31,9 3,9 2
	d) Employee benefits expense e) Depreciation and amortisation expense f) Impairment / (Reversal) g) Finance Costs h) Other expenses	4,846 684 - 15 6,272	5,743 692 - 19 6,050	6,073 589 (213) 21 8,260	16,653 2,024 - 52 19,171	15,077 2,160 (61) 60 23,097	20,6 2,8 33,7
	Total expenses (4)	19,203	21,543	24,736	63,039	67,130	93,3
5.	Profit before exceptional items and tax (3-4)	6,272	9,972	7,853	25,049	27,007	31,4
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	6,272	9,972	7,853	25,049	27,007	31,4
8.	Tax expenses Current Tax Deferred Tax Tax for earlier years	1,630 (14) -	2,772 (191) 184	2,271 (337) -	6,631 (186) 184	7,468 (426) -	8,6 (5 3
9.	Net Profit for the period/ year (7-8)	4,656	7,207	5,919	18,420	19,965	22,9
10.	Other Comprehensive Income Items that will not be reclassified to profit or loss i. Re-measurement gains/(losses) on defined benefit plans ii.Income tax effect Total Other Comprehensive Income, net of tax	177 (44) 133	115 (29) 86	236 (59) 177	224 (56) 168	(305) 77 (228)	(2 (1
11.	Total Comprehensive Income for the period/year (9+10)	4,789	7,293	6,096	18,588	19,737	22,7
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660	1,660	1,660	1,660	1,660	1,6
13. 14.	Other equity excluding Revaluation reserve as per Balance sheet Earnings per equity share (of Rs 10/- each) *(not annualised)	-	-	-	-	-	73,4
	(a) Basic and Diluted (in Rs.)	* 28	* 43.4	* 35.7	* 111	* 120.3	13

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1.	The above unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on May 2, 2024 and have been subjected to a limited review by the Statutory
	Auditors of the Company.

- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- 3. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 Operating Segments. Accordingly no separate segment information has been provided.
- 4. The Board of Directors at its meeting held on February 6, 2024 have declared for the current year an interim dividend of ₹ 200 per equity share of face value ₹ 10 each (including a one-time special dividend of ₹ 150 per equity share) aggregating to ₹ 33,199 lakhs.
- 5. During the Quarter, certain employees opted for the Company's existing voluntary retirement scheme. Employee cost includes expense amounting to ₹ 259 lakhs (or the previous quarter ended 31st December 2023 expense of ₹ 1,180 lakhs & for the period ended 31st March 2024 expense of ₹ 2,886 lakhs) in this regard.

For and on behalf of the Board of Directors of Procter & Gamble Health Limited.

Milind Vasant Milind Vasant Thatte Thatte

> Milind Thatte Managing Director DIN 08092990

Place : Mumbai Date : May 2, 2024 Please visit us at our website www.pghealthindia.com

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors Procter & Gamble Health Limited

- We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended March 31, 2024 and for the period from July 01, 2023 to March 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of

HARIBHAKTI & CO. LLP

Chartered Accountants

Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP **Chartered Accountants** ICAI Firm Registration No.103523W/W100048 DEEPAK G Digitally signed by DEEPAK G MOROLIA MOROLIA Date: 2024.05.02 19:47:40 +05'30'

Deepak G. Morolia Partner Membership No.: 130533 UDIN: 24130533BKFEBZ2072

Place: Mumbai Date: May 02, 2024